Emerging biomarkers for the detection of cardiovascular diseases

Sreenu Thupakula¹, Shiva Shankar Reddy Nimmala¹, Haritha Ravula², Sudhakar Chekuri³ and Raju Padiya¹*

Abstract
Background: The prevalence of cardiovascular disease (CVD) has been continuously increasing, and this trend is projected to continue. CVD is rapidly becoming a significant public health issue. Every year there is a spike in hospital cases of CVD, a critical health concern in lower- and middle-income countries. Based on identification of novel biomarkers, it would be necessary to study and evaluate the diagnostic requirements or CVD to expedite early detection.

Main body: The literature review was written using a wide range of sources, such as well-known medical journals, electronic databases, manuscripts, texts, and other writings from the university library. After that, we analysed the specific markers of CVD and compiled a systematic review. A growing body of clinical research aims to identify people who are at risk for cardiovascular disease by looking for biomolecules. A small number of biomarkers have been shown to be useful and reliable in medicine. Biomarkers can be used for a variety of clinical applications, such as predicting heart disease risk, diagnosing disease, or predicting outcomes. As a result of the ability for a single molecule to act as a biomarker, its usefulness in medicine is expected to increase significantly.

Conclusions: Based on assessing the current trends in the application of CVD markers, we discussed and described the requirements for the application of CVD biomarkers in coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other cardiovascular illnesses. Furthermore, the current review focuses on biomarkers for CVD and the procedures that should be considered to establish the comprehensive nature of the expression of biomarkers for cardiovascular illness.

Keywords: Biomarkers, Biomolecular systems, Cardiovascular disease, Cardiac markers, Diagnosis, Therapeutics

Background
Coronary heart disease (CAD), cerebrovascular disease (CD), rheumatic heart disease (RHD), and other cardiovascular illnesses are non-communicable diseases and leading causes of global mortality [1]. CVD produces more fatalities yearly than any other disease, accounting for 17.9 million deaths per annum, which is about 31% of all worldwide deaths. Coronary heart disease claimed the lives of 7.3 million people, while stroke claimed the lives of 6.2 million [2]. By 2030, 23.6 million individuals will have died from CVD, principally heart disease and stroke. Biomarkers are used to diagnose and monitor cardiovascular disease to reduce the mortality rate [3].

Cardiac biomarkers are bio-molecular components obtained through venal punctures and secreted in the blood during an injured or strained heart [4]. Heart biomarker tests may assist in evaluating a person’s risk of cardiac illnesses and monitoring and treating someone suspected of having an acute coronary syndrome (ACS) and cardiac ischemia. Biomarkers are a powerful tool for identifying high-risk people, promptly and reliably diagnosing illness conditions, and effectively diagnosing and treating patients [5, 6]. Most other biomarkers seem to be up-regulated or down-regulated in illnesses other than CVD. Current trends in identifying the number of biomarkers that may consistently aid prognosis in the early...
The stages of the disease are limited. This review provides an overview of commonly used CVD biomarkers based on the carbon skeleton from which they are formed. Some of their merits and drawbacks, proposing a method for future, innovative biomarker research are shown in Fig. 1 and Table 1.
## Table 1  Notable emergent biomarkers in cardiovascular diseases

| Name of Marker          | Derivative of | Source of tissue | Cause of increase                                      | Time point to increase | Time point to back normal | Diagnostic use                                                                 |
|-------------------------|---------------|------------------|--------------------------------------------------------|------------------------|---------------------------|--------------------------------------------------------------------------------|
| Cardiac troponin        | Regulatory protein complex. T and I cardiac-specific isoforms | Heart | Heart injury                                           | 3–4 h after injury     | 7–10 days                 | Myocardial infarction and degree of damage                                      |
| C reactive protein      | Protein derived. Acute phase protein | Liver | Raise in Inflammation                                  | 4–6 h after inflammation| Decrease (36–50 h) after resolution of inflammation | Chronic inflammatory disease and risk of heart disease |
| Myeloperoxidase         | Protein derived | azurophilic granules of polymorphonuclear neutrophils and macrophages | Coronary artery disease and Inflammation | 2 h after onset of symptoms | –                         | Diagnosis and risk stratification of acute coronary artery syndrome             |
| CK-MB                   | Myocardium-related isoenzymes of CK | Heart and Skeletal muscles | When injury to heart and skeletal muscle cells | 4–6 h after heart muscles injury, peak level at 24 h | Within 48–72 h, it will return to normal | Less than Troponin in specificity. Used to diagnostic re-infarction             |
| Ischemia modified albumin (IMA) | Protein derived | Heart tissue | when circulating serum albumin contacts ischemic heart tissues | Rise within minutes of transient ischemia. Peak within 6 h | –                         | It is a good discriminator between ischemic and non-ischemic patients          |
| Myoglobin               | Protein derived, oxygen sorting protein | Hearty and skeletal muscles | When injury to heart and skeletal muscle cells | After injury 2–4 h, peak level at 8 to 12 h | Return to normal within 24 h | Early diagnosis in addition to Troponin                                        |
| Fibrinogen              | Glycoprotein   | Liver            | Tissue and vascular injury, it may elevate in inflammation | 5 days after injury    | –                         | Bleeding disorders and risk of cardiovascular diseases                      |
| TMAO                    | Amino acid derivative | Intestinal lumen | Cardiovascular and Renal disease | Increase within 24 h | –                         | To predict heart attack, stroke and kidney disease                             |
| Cystatin- C             | Protein derivative | All nucleated cells | Acute kidney injury and cardiovascular disease | When acute kidney injury develops, after 8 h of cardiac surgery | –                         | Early detection of acute kidney injury in cardiac surgery patients             |
| Lipoprotein-associated phospho lipase A2 | Lipid derivative | Leukocytes | Cardiovascular inflammation and heart failure | After 24 h of inflammation | –                         | To help to determine risk of CVD’s and coronary heart disease and ischemic stroke |
| Oxylipins               | Lipid derivative | All nucleated cells | Increased in cardiovascular diseases |                       |                            | Develop early diagnostic tools for CVD’s                                        |
Main text

Carbohydrate-based biomarkers

Glycogen phosphorylase BB (GPBB)

The heart is highly susceptible to CO (carbon monoxide)-induced hypoxia due to its high oxygen demand. Due to a lack of apparent symptoms or specific electrocardiogram (ECG) changes, CO poisoning in cardiovascular patients may go undiagnosed and untreated. The importance of early and particular markers for myocardial hypoxia is growing. One candidate is the glycogen phosphorylase BB isoenzyme (GPBB) [7–9]. GPBB is a novel cardiac marker that might help identify myocardial ischemia early [10–12]. In hypoglycaemia or hypoxic settings, GPBB is an important enzyme that catalyses the first rate-limiting step in the degradation of glycogen to glucose 1-phosphate [13, 14].

In humans, three distinct isoforms have been identified: GPMM (present in muscles), GPLI (liver), and GPBB (brain). The diagnostic sensitivity of myoglobin and ischemia-modified albumin (IMA) is good. However, there is no heart muscle specificity [15]. GPBB is a more sensitive marker for diagnosing ACS within 4 h after the beginning of chest pain [16, 17], with a sensitivity of 81% and a specificity of 93%. This research revealed that GPBB is an excellent clinical marker of ischemia and may be used to diagnose ACS [15]. Although there is an expected increase in plasma GPBB concentration during pregnancy, which is also seen in the brain, there is no absolute specificity for identifying the cardiac injury. GPBB in plasma is a surrogate marker for acute coronary syndromes in many investigations [11, 16, 18]. As a result, GPBB may be employed as a secondary biomarker for detecting acute myocardial infarction [12].

Protein-based biomarkers

Aspartate aminotransferase (AST)

Aspartate aminotransferases, also called liver transaminases, are intracellular enzymes catalysing the transamination reaction between amino acids and ketonic acid [19]. Because it is present mainly in hepatocytes, AST is a commonly used serum marker of liver disease. Recent research has shown that liver transaminases can independently predict cardiac-related morbidity and mortality. The first cardiac biomarker, AST, was discovered in the liver, heart, skeletal muscle, brain, and kidney in 1954. It does not help diagnose AMI due to the lack of specificity of cardiac tissue [20, 21].

Total CK levels were tested for AMI in 1959 because it was an excellent indicator of skeletal muscle damage[22]. In 1960, LDH was used to diagnose AMI [23]. Finally, in 1979, the World Health Organization (WHO) approved a panel of CK, AST, and LDH to diagnose AMI [24].

Lactate dehydrogenase (LDH)

The intracellular enzyme lactate dehydrogenase (LDH), which is widely distributed, catalyses the conversion of pyruvic acid, the final by-product of the glycolytic process, to lactate. Since the 1960s, LDH has been employed to diagnose acute myocardial infarction as a marker of heart dysfunction. LDH is composed of two self-contained subunits, resulting in the formation of five isozymes. Each isozyme is expressed in a distinct organ: LDH1 is expressed in cardiomyocytes, LDH2 is found in lung tissue, and LDH3 is expressed in hepatocytes [25, 26]. Many organs, including skeletal muscle, kidney, liver, heart, lung, and erythrocytes, express LDH. LDH contains five isozymes, one of which is found in nature. Although it has been reported that an LDH1-to-LDH2 ratio higher than 1 is specific for AMI, it is presently not employed in diagnosing AMI [27]. LDH is now only used to differentiate acute from subacute myocardial infarction (MI) in patients with positive troponins whose CK and CK-MB readings have reverted to normal levels when they arrive at the hospital late in the disease [28].

Carbonic anhydrase III (CA-III)

Red blood cell primary protein constituents, carbonic anhydrases (CAs), are zinc-containing metalloproteinases that accelerate the hydration and dehydration of carbon dioxide [29]. CAs are found in various tissues and participate in multiple physiological functions, including gluconeogenesis, acid–base homeostasis, adipogenesis, and calcification [30]. CA-III protein is a unique member of the CAs family; it has a role in various disorders, including type-2 diabetes, MI, and skeletal muscle injury. CA-III protein is a cytosolic enzyme with lower activity than carbon dioxide hydratase [31]. It has been shown to scavenge oxygen radicals in vivo and increase survival from oxidative injury. The cytosolic isofrom CA-III is abundant in skeletal muscles [32]. This enzyme possesses antioxidative properties and is critical for maintaining intracellular pH homeostasis. Given that high blood CA-III levels, often in conjunction with other muscle-specific proteins, are commonly used to diagnose overall muscle injury, it seemed worthwhile to review current CA-III investigations [33].

Brain natriuretic peptide (BNP and NT-pro BNP)

As a result of myocardial stretching, BNP and 32 amino acid (-a.a) N-terminal (NT)-proBNP are continually released from the ventricles into the bloodstream. The prohormone brain natriuretic peptide (proBNP), a 108-a.a peptide cleaved into the 76-a.a BNP and 32-a.a. NT-proBNP, is produced as a result [34]. A sixfold increase in half-life compared to that of BNP is seen, and the peptide
is eliminated from the body by many processes, including those involving the renal system and other systems [35]. BNP and NT-proBNP are high in individuals with heart failure, making them valuable diagnostic indicators for the disease. Brain natriuretic peptide (BNP) regulates several physiological and pathological processes [36]. BNP has been demonstrated to be involved in natriuresis, diuresis, vasodilatation, and inhibition of the sympathetic nervous system in addition to the renin–angiotensin–aldosterone system [37, 38]. Studies have shown that the function of BNP also influences diseases associated with the pathways mentioned above to a certain extent [39].

**Mid-regional pro-a-type natriuretic peptide (MR-pro-ANP)**

Natriuretic peptides are the gold standard in heart failure biomarkers and have been thoroughly researched in many clinical settings [40, 41]. In particular, B-type natriuretic peptide (BNP) is generated from scratch in response to ventricular stretch brought on by pressure and volume overload in both healthy adults and patients with left ventricular (LV) dysfunction [42]. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is an essential cardiac biomarker that correlates well with left ventricular end-diastolic pressure and wall pressure. It has high sensitivity and specificity for the differential diagnosis of HF in patients with acute dyspnoea and has significant value in the diagnosis, evaluation, and prognosis of patients with either acute or chronic HF. Recently, a mid-regional sequence of pro-a-type natriuretic peptide (MR-pro-ANP), which is a more stable intermediate of the natriuretic peptides, was effectively employed in the clinical as a biomarker of prognosis and diagnosis of acute HF [18, 43].

**Mid-regional pro-adrenomedullin (MR-proADM)**

Adrenomedullin (ADM) is a vasoactive peptide in a human pheochromocytoma3 tumour. Even though a few organs and tissues produce ADM, it is principally synthesized by vascular endothelial cells and has a wide range of physiological functions [44, 45]. Patients with hypertension, congestive heart failure or myocardial infarction, renal disorders (including kidney failure and diabetes mellitus), acute phase of stroke (including septic shock), and arterial stiffness have been observed to have higher plasma ADM levels (including arterial stiffness). The magnitude of the increase is proportional to the severity of the vascular damage [46]. Sepsis, acute dyspnoea, acute and severe chronic HF with decreased ejection fraction (HFREF), and HF with preserved ejection fraction are all illnesses that are associated with higher levels of the neurohumoral marker of cardiac biochemical stress known as MR-pro-ADM (HFPEF) [47]. There is evidence that MR-proADM is an early predictor of in-hospital mortality owing to various causes, including respiratory infections, surgical procedures, and cardiovascular illness [48, 49].

**Endothelin-1 (CT-proET-1)**

Endothelin-1, a potent vasoconstrictor and potentiator of sympathetic neurohormones generated in blood vessel endothelial cells, is also a sympathetic activation marker. In heart failure, plasma levels of both endothelin-1 and large endothelin-1 are elevated and are linked to pulmonary artery pressure, disease severity, and death [50, 51]. CT-1 and adrenomedullin (ADM) levels in the blood are more significant in people with heart failure than in healthy individuals. It is believed that endothelin has a role in forming pulmonary vasoconstriction, smooth muscle cell proliferation, and remodelling the pulmonary vascular system [52]. In light of this, our team proposed that C-terminal pro-endothelin-1 (CT-proET-1) and mid-regional pro-adrenomedullin (MR-proADM) levels would be higher in heart failure patients compared to controls, and that the degree of this elevation would be related to cardiopulmonary reserve [53, 54]. C-terminal pro-endothelin-1, a newly discovered stable endothelin-1 surrogate marker, has also been proposed as a prognosticator. Increased levels of CT-proET-1, MR-proANP, and MR-proADM were independently linked with the risk of cardiac mortality or heart failure in a recent investigation on patients with stable coronary artery disease after adjusting for clinical cardiovascular risk factors and ejection fraction [55].

**Creatine kinase-MB (CK-MB)**

A blood test for creatine kinase has been used to identify myocardial infarction since the 1960s. Because of the discovery of CK-MB, one of three creatine kinase isoenzymes found mainly in the heart, researchers have increased the accuracy of myocardial damage diagnosis and have used it to evaluate acute myocardial infarction (AMI) since the 1970s. CK-MB is one of three isoforms of the creatine kinase enzyme, which is present mainly in the heart but also at minor levels in skeletal muscle [56]. Creatine kinase levels are often elevated in myocardial infarction. As a result, the CK-MB is used to determine whether the elevated creatinine level is due to skeletal or cardiac muscle damage [57].

**Hydroxybutyrate dehydrogenase (HBDH)**

The determination of serum hydroxybutyrate dehydrogenase (HBDH) activity may be used to diagnose myocardial infarction without the necessity for isoenzyme separation [58, 59]. Raised serum HBDH activity is uncommon in liver disorders, as one would assume [60]. HBDH levels rise in the blood for 8 to 10 h after a heart attack and
then rise again in 2–4 days. They may stay high for up to 18 days, which is a considerable period compared to other heart attack indications [60].

Heart-fatty acid binding protein (H-FABP)
Heart-fatty acid binding protein (H-FABP) is a low molecular weight cytosolic protein in cardiac tissues that transports fatty acids from the plasma membrane to oxidation sites in mitochondria and peroxisomes, as well as to the endoplasmic reticulum for lipid synthesis [61]. It is primarily found in the myocardium and the brain, kidneys, and skeletal muscle to a lesser level. H-FABP is released into the serum after myocyte rupture very early [62]. H-FABP levels rise as soon as 30 min after myocardial infarction, peak at 6–8 h, and then return to baseline after around 24 h [63]. Aside from that, H-FABP has the potential to be employed as a predictive biomarker of mortality [64].

Cardiac Troponin
Cardiac troponin is a calcium-dependent regulator of the heart muscle’s contraction mechanism, frequently referred to as a “switch” between contraction and relaxation. For myocardial infarction, cardiac troponin is presently the gold standard biomarker test. Troponin T (TNT), troponin I (TNI), and troponin C (TNC) are the three components of the cardiac troponin complex. Because the amino acid sequences of skeletal and cardiac isoforms of TNT and TNI differ significantly, monoclonal antibody-based immunoassays have been designed to detect cardiac-specific TNT and cardiac-specific TNI.

ACS patients benefit from cardiac troponins because they are sensitive, specific, and offer symptomatic information. As a result, troponin is now the preferred cardiac marker in individuals with ACS. They are also more susceptible to minor degrees of myocardial injury than CK-MB tests. Even though it is the gold standard marker for myocardial infarction, it has minimal usefulness in the diagnosis of reinfarction. A second myocardial infarction that occurs 7 to 10 days after the first may be difficult to identify with cardiac troponin tests alone due to its extended half-life [65].

C reactive protein (CRP)
The liver secretes C reactive protein (CRP), one of the acute phase proteins. In reaction to numerous inflammatory cytokines, their content in the blood is quickly growing [66]. More evidence has been gained in recent years concerning the likely involvement of inflammation in developing significant health disorders such as diabetes or heart disease. According to many epidemiological studies, CRP is a powerful independent predictor of future cardiac events, including myocardial infarction, ischemic stroke, peripheral vascular disease without a known heart disease, and sudden cardiac death [67]. This protein is significant because it occurs early in the bloodstream during numerous systemic inflammatory disorders. Lower stability, a lengthy detection period, and cross-reactivity with other blood proteins are some drawbacks in diagnosing this protein [68].

Tumour necrosis factor (TNF-α)
Tumour necrosis factor (TNF-α) is an inflammatory cytokine that is elevated in chronic HF patients [69]. TNF-α has also been linked to aberrant left atrial dysfunction and advanced left ventricular diastolic and systolic dysfunction disease severity in patients with newly diagnosed HF [70], as well as the use of TNF-α as a predictor of death in advanced HF patients [71].

Interleukin-6 (IL-6)
Interleukin-6 (IL-6) is a cytokine that has a role in inflammation, but it also has cardiovascular effects via regulating cardiomyocyte hypertrophy and apoptosis [72]. Cardiac IL-6 expression has been shown to rise in advanced HF, indicating that it may have a role in prognosis [73]. Furthermore, elevated IL-6 levels have been linked to left ventricular dysfunction before HF diagnosis, suggesting that it might be used as a risk marker for the start and progression of HF [74]. This finding suggested that IL-6 may play a role in distinguishing between the decompensated and compensated phases [75].

Pentraxin 3 (PTX-3)
In response to an inflammatory stimulus, vascular endothelial cells, smooth muscle cells, macrophages, and neutrophils generate PTX-3, a unique marker of vascular inflammation [76]. In patients with unstable angina pectoris, myocardial infarction, and heart failure, the PTX-3 level has been recommended as a predictive biomarker of poor prognosis [77, 78]. PTX-3, on the other hand, predicts advanced atherosclerosis and is more specific for artery wall inflammation than CRP [79].

Pregnancy-associated plasma protein A (PAPPA)
A metalloproteinase called pregnancy-associated plasma protein A (PAPPA) is crucial for the rupture of atherosclerotic plaque [80]. The leading producers are the placental syncytiotrophoblast, fibroblasts, vascular endothelial cells, and vascular smooth muscle cells. It has been linked to plaque progression and instability in atherosclerosis [81].
A soluble cluster of differentiation 40 ligands (SCD40L)
The TNF-α family member SCD-40 L is increased on platelets in the intraluminal thrombus. The release of CD40L into the circulation occurs when the inflammatory and coagulant pathways are activated during thrombogenesis, signifying plaque rupture and eventually myocardial infarction [82].

Copeptin
The cleavage of pre-PR vasopressin yields copeptin, neureophysin ii, and vasopressin, the latter of which is sometimes referred to as antidiuretic hormone and is crucial for fluid balance and has been associated with the severity of HF [83]. Vasopressin is known to be unstable in circulation, making clinical measures difficult. On the other hand, copeptin is thought to have better stability and is produced in equimolar amounts to vasopressin, making it a more dependable and repeatable option for indirect vasopressin detection [84]. Copeptin may thus be utilized as a diagnostic and prognostic marker for myocardial infarction [85].

Growth differentiation factor-15 (GDF-15)
Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor (TGF) family of cytokines primarily produced by the placenta and implicated in tissue damage inflammatory and apoptotic pathways. GDF-15 levels over a certain threshold have been proven to indicate high-risk individuals with cardiovascular disease [51, 86–88]. Increased GDF-15 levels have been linked to the promotion of protective mechanisms for inhibiting apoptosis, hypertrophy, and adverse remodelling in patients with chronic HF, with increased expression of GDF-15 related to the advancement of protective means for inhibition of apoptosis, hypertrophy, and adverse remodelling [89].

F2 Isoprostanes
Arachidonic acid metabolism produces F2 isoprostanes. F2 isoprostanes are released by a few cells, including monocytes, during atherosclerosis. The amount of F2 isoprostane in the urine of individuals with unstable angina is higher in studies. It may also be utilized as a predictor of complications in non-fatal myocardial infarction, the progression of heart failure, and fatality [90].

Suppression of tumorigenicity 2 (ST2)
Suppression of tumorigenicity 2 (ST2) is an interleukin (IL)-1 receptor that has been discovered as a target for IL-33, a cytokine produced when the heart is under metabolic stress [90]. ST2 is a soluble protein produced by cardiomyocytes and detectable in the bloodstream. Its levels rise in response to mechanical stress on the heart [91]. Its utility in HF has been recognized as an independent predictor of mortality or the need for transplantation in patients with severe chronic HF [92], as providing prognostic information for patients with acute HF when combined with natriuretic peptides [93], implying that it could be used as a biomarker in conjunction with current clinical testing strategies like BNP and NTPROBNP.

Matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP)
Cardiac extracellular matrix remodelling is an essential mechanism in the development and progression of HF. This remodelling is partly mediated by collagenases, MMP, and TIMP, which degrade collagen and other matrix proteins [94]. Fibrosis and ventricular remodelling may result from an imbalance between MMPs and TIMPs. Excessive collagen crosslinking has been linked to HF hospitalization in hypertensive individuals, according to a new study [95]. George et al. revealed that MMP-2 (but not MMP-3, -9, or TIMP-1) concentrations were an independent predictor of death in patients with HF in the first MMPs investigations [96]. MMP-3 and MMP-9 were univariate indicators of all-cause mortality in patients with HFREF. Only MMP-9 emerged as a poor independent prognosis, according to Buralli et al. [97]. TIMP-1, but not MMP-9, was shown to be of separate and additional value in Frantz et al’s prediction of all-cause mortality [98, 99].

Galectin-3
Galectin-3 is implicated in tissue healing, myofibroblast proliferation, and fibrogenesis in the inflammatory pathway after injury and ventricular remodelling. Galectin-3 instillation into the pericardium resulted in a considerable increase in collagen deposition [100]. Galectin-3 is elevated in patients with acute or chronic HF, and univariable analyses are frequently associated with risk, but with adjustment for renal function or other biomarkers, galectin-3 loses its prognostic meaning in many studies [101, 102]. Serial galectin-3 measurements in chronic HF patients may contribute to a single measure, but no known medications may change galectin-3 readings at this time [103].

Procalcitonin
Procalcitonin is a pro-peptide of calcitonin typically produced by parafollicular C cells in the thyroid gland [104]. Calcium homeostasis and immunity are regulated by pro-calcitonin/calcitonin axed [105]. There is insufficient proof that serum procalcitonin levels are a reliable marker for chronic HF with predictive value, although serial procalcitonin measurements are advised to differentiate between in-hospital mortality in a variety of
diseases associated with pro-inflammatory activation (pneumonia, chronic obstructive pulmonary disease, acute respiratory tract infections, etc.) [106]. Extensive clinical studies are needed to fully clarify the hypothesis and gather further information about the predictive significance of pro-calcitonin in HF patients with worsened symptoms.

Comorbidities
Renal dysfunction, hematologic abnormalities, and liver dysfunction are all critical indicators of a poor prognosis in heart failure. While serum creatinine, estimated glomerular filtration rate, and blood urea nitrogen are essential indices of renal function, NT-ProBNP provides additional prognostic information [107]. Their predictive significance is lower at lower levels of impairment, and the commencement of these biomarkers’ increase is often delayed following acute renal injury (AKI). Cystatin C and trace protein (BPT) outperformed standard renal indicators in predicting prognosis in HF, owing to its improved capacity to assess renal function at lower degrees of abnormalities [108].

While high levels of NAGL are linked to poor clinical outcomes, this link was lost after controlling for many factors, including NT-ProBNP [109]. Furthermore, it has a reasonable capacity to predict impending AKI (68% sensitivity and 70% specificity) [110]. KIM-1 in the urine and NAG in the blood showed potential, but further research is required. Hematologic abnormalities, including anaemia, iron deficiency, and increased red blood cell distribution width (RDW), are common in HF patients and play an essential role in predicting prognosis, independent of LVEF [111]. It is uncertain if correcting hematologic abnormalities can enhance clinical outcomes in HF patients.

Myeloperoxidase (MPO)
Myeloperoxidase (MPO) is an enzyme secreted into an extracellular fluid by polymorphonuclear neutrophils and macrophages’ azurophilic granules during inflammation. A valuable risk marker and diagnostic tool in acute coronary syndrome and chest discomfort are myeloperoxidase, which is implicated in oxidative stress and inflammation [112]. High concentrations of MPO, irrespective of traditional CVD risk factors, have been demonstrated to enhance CVD risk in epidemiological investigations [113, 114]. MPO is implicated in all phases of endotheliosis, from endothelial dysfunction to plaque rupture, according to in vitro studies, and it is involved in the initiation of CVD and acute cardiovascular events [115]. Since both myoglobin and haemoglobin have peroxidase activity and the substrate for myeloperoxidase (MPO) and general peroxidase is the same, detecting them is problematic [116].

Fibrinogen
In 1836, fibrinogen was identified and characterized as the first clotting agent [117]. Cells participating in the atherogenic process may produce cytokines, which trigger an acute phase response that raises plasma fibrinogen levels [118]. Fibrinogen is a significant acute phase protein that creates the substrate for thrombin and constitutes the last stage in the coagulation cascade [119]. According to research, fibrinogen is a significant and independent cardiovascular risk factor related to established risk factors and genetic variants. Despite unsolved difficulties requiring definitive solutions, fibrinogen has emerged as an essential new predictor of cardiac risk [120] since we may detect low fibrinogen levels in individuals with severe hepatic illness [121].

Trimethylamine n-oxide (TMAO)
Trimethylamine n-oxide (TMAO) is a dietary metabolite linked to red meat consumption. Liver enzymes produce TMAO from the gaseous precursor trimethylamine (TMA), which is created when gut bacteria break down these nutrients [122]. In all diets, red meat has the highest concentration of l-carnitine, increasing the quantity of l-carnitine accessible for TMAO production. While a recent study has proven that high levels of TMAO in the blood are linked to an elevated risk of heart disease and death, it shows that TMAO may be used as a biomarker for both heart and kidney illness [123].

Cystatin C
Most nucleated cells regularly produce and release cystatin C, a tiny protease inhibitor. It is a well-described blood marker of renal failure in clinical practice. In addition, because of decreased renal function and the relationship between cardiac risk and illnesses, cystatin C is being studied as a cardiac marker [124].

Myoglobin
Myoglobin is an oxygen-binding protein that forms a compound with iron molecules in skeletal and cardiac muscle tissues. One hour after myocardial infarction, it is released into circulation. Within 2 to 4 h after the commencement of myocardial damage, it steadily rises, peaks in 8–12 h, and recovers to normal in 24–36 h. Due to substantial levels of myoglobin in skeletal muscles, myoglobin is an early indication of acute myocardial infarction but lacks cardiac specificity. Myoglobin should not be used alone to confirm a diagnosis of acute myocardial infarction; instead, it should be combined with other
heart-specific markers like TNI or TNT to boost diagnostic value [125].

Ischemia-modified albumin (IMA)
When serum albumin from ischemic cardiac tissues comes into touch with IMA, it becomes a new sign of ischemia. The albumin cobalt binding test, based on the inability of IMA to bind cobalt, has been developed and commercialized as the first commercially accessible FDA-approved diagnostic of myocardial ischemia with a 30-min laboratory turnaround time [126]. IMA may distinguish ischemic and non-ischemic patients. Because IMA is elevated in illnesses other than chest pain, its ineffectiveness calls into doubt its specificity. Even while IMA assessment remains the sole clinical biomarker for myocardial ischemia, the process of IMA generation and the precise unit being evaluated are unknown [127].

Endothelial dysfunction (noninvasive method)
Endothelial cells are a monolayer of active cells lining the inside blood and lymphatic arteries. It acts as an active paracrine, endocrine, and autocrine organ to maintain vascular homeostasis [128]. It controls oxidative stress, as well as both local and systemic inflammation. According to current research on atherosclerosis and the basic mechanisms involved, harmful changes in endothelial physiology and biology, also known as endothelial dysfunction, may be a critical early step in the development of atherosclerosis and may also signal lesion progression and the occurrence of complications [129, 130]. Endothelial dysfunction is an independent predictor of poor cardiovascular outcomes and may have more predictive power than established risk variables alone in predicting future cardiovascular events [131].

Apoptosis antigen-1 (APO1/FAS)
FAS, also known as apoptosis antigen-1 (APO1), is a TNF family member that regulates apoptosis. FAS is present in the thymus, liver, ovary, lung, and heart, among other organs [132, 133]. FAS is increased in cardiomyocytes due to apoptotic cell death caused by hypoxia and overstretching [134]. A soluble version of FAS (SFAS) missing the transmembrane domain was also discovered in human serum [133], and its levels are expected to be higher in individuals with cardiovascular disease. Individuals with severe CHF had considerably greater SFAS levels in their blood than patients with moderate CHF. Furthermore, stepwise multivariate analysis revealed that individuals with high SFAS and BNP and a poor ejection fraction had a substantially greater mortality rate than those with low SFAS levels, indicating that plasma SFAS is a helpful prognostic marker in CHF aetiology.

Neutrophil gelatinase-associated lipocalin (NGAL)
Neutrophil gelatinase-associated lipocalin (NGAL) is a lipocalin protein having a polypeptide chain of 178-a.a and a molecular mass of 25 KDa expressed by neutrophils and different epithelial cells express [135, 136]. NGAL expression is elevated under acute phase protein [137, 138]. NAGL seems to be one of the first kidney indicators of nephrotoxic and ischemia damage in animal models, and it is shown to be high in the urine and blood of people shortly after acute injury (AKI) [138]. Compared to control participants, chronic HF patients had more significant amounts of NGAL in both blood and urine [139]. NGAL seems to function as a biomarker in the case of acute HF, according to research by Damman et al. As a result, further study into the function of NGAL in acute and chronic heart failure might be beneficial [140].

Uric acid (UA)
In humans, uric acid (UA) is the final product of purine metabolism. The inactivation of uricase and the subsequent rise in UA levels are hypothesized to have offered evolutionary benefits by guarding against oxidative damage [141]. Increased serum UA, even below the clinical threshold for hyperuricemia, has been linked to the development of CVD through increasing oxidative stress, inducing endothelial dysfunction, and boosting inflammation [142]. Recent research has shown an independent link between UA and cardiovascular mortality [143, 144]. However, the evidence supporting the outcomes is still inconclusive. Numerous epidemiological investigations, including prospective, retrospective, cross-sectional, and meta-analysis studies, have failed to find an independent link between UA and CVD [145, 146].

Neuregulin-1 (NRG-1)
Endothelial cells emit neuregulin-1 (NRG-1), which binds to a family of ERBB receptors on neighbouring cardiac myocytes to enhance cell survival, growth, and maintenance [147]. The NRG-1 gene has been linked to more than 15 distinct protein products. The most prevalent NRG-1 protein in the cardiac system is NRG-1. The paracrine impact of the NRG-1 ligand is mediated by the ERBB (ERBB2, ERBB3, ERBB4) tyrosine kinase receptor family. NRG-1 is activated by various cardiovascular stressors, including oxidative stress, ischemia, and exercise [148]. As a result of NRG-1/ERBB4 paracrine signalling in the heart, this system may be engaged in cardiac adaptation to different types of physiologic stress. NRG-1 levels were associated with more advanced stages of HF and a poorer outcome in HF patients with CAD [149]. Increased blood levels of NRG, like NT-PROBNP, may be an insufficient physiologic response to cardiovascular
injury, and exogenous treatment of NRG may enhance cardiovascular function. These data support the theory that NRG-1 in the myocardium is activated in response to ischemia. NRG-1’s potential as a CVD biomarker needs further investigation.

**Human serum albumin (HAS)**
Albumin is a significant protein in human plasma made by liver cells. Albumin has a variety of activities, including controlling fluid filtration and adsorption across capillary walls and transporting various chemicals in the bloodstream. Albumin concentrations are often evaluated in blood or urine and may be used as indicators of dehydration, malnutrition, liver or kidney illness, and cardiovascular disease [150].

**Serum amyloid A (SAA)**
The serum amyloid A (SAA) protein belongs to a group of apolipoproteins that are usually linked to high-density lipoproteins (HDL). When interleukin-6 (IL-6) is stimulated in response to infection, inflammation, injury, or stress, the acute phase SAA proteins SAA1 and SAA2 are released into the blood. Binding phase proteins are being examined extensively as possible indicators for predicting the progression of cardiovascular illnesses, and SAA has shown to be a promising candidate for a cardiac biomarker [151, 152].

**Retinol-binding protein 4 (RBP4)**
Retinol-binding protein 4 (RBP4) is a member of the lipocalin protein family that serves as a carrier protein for vitamin A in serum. RBP4 has been shown to have a critical role in insulin resistance. Several studies have recently revealed that RBP4 levels in the blood may be linked to cardiovascular disease and metabolic syndrome [153, 154].

**Soluble lectin-like oxidized LDL receptor (SLOX-1)**
The extracellular domain of LOX-1 is proteolytically cleaved to form the soluble lectin-like oxidized LDL (SLOX-1) receptor. LOX-1 is a transmembrane protein present on the cell surface of endothelial cells and smooth muscle cells, among other places. SLOX-1 has been suggested as a biomarker for plaque rupture in a few studies, and it may have clinical usefulness in detecting atherosclerosis-related disorders [155, 156].

**Adiponectin (ADN)**
Adipokines are a kind of protein hormone abundant in the human body. It is a crucial lipid and glucose metabolism regulator predominantly expressed by adipocytes. According to research, ADN is an insulin sensitizing hormone with anti-diabetic, anti-inflammatory, and anti-atherogenic characteristics. ADN levels in the blood have been linked to various lifestyle disorders, including atherosclerosis and heart failure [157, 158].

**S100 protein**
S100 proteins have a molecular weight of 10 to 12 KDa and are acidic calcium-binding proteins. In humans, there are over 20 distinct members of this family. These proteins seem to be involved in various biological activities, including cell proliferation and differentiation, as well as the inflammatory response. The involvement of several family members (S100B and S100A) in heart illness has been investigated [159].

**Lipid derived biomarkers**

**Triglyceride-to-high-density lipoprotein cholesterol ratio**
Triglyceride (TG) to high-density lipoprotein cholesterol ratio (HDL-C) and total cholesterol (TC)-to-HDL ratio, as well as a low ankle branchial pressure index (ABPI), are vital biomarkers for CVD [160]. Although triglyceride levels may be seen in most routine lipid panels, they can also be utilized to predict CVD risk by combining them with other lipid profile indicators [160]. A triglyceride-to-HDL cholesterol ratio of more than 3.5 seems to be linked to an elevated risk of cardiovascular disease. Apolipoprotein B (APO-B), lipoprotein A (LPA), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) elevations are reported during HF. Important biochemical markers include a considerable drop in apolipoprotein A1 (APOA1), APOA1/APOB ratio, and PON1 activity/HDL ratio [161]. People with type 2 diabetes mellitus (T2DM) who have higher levels of LDL, triglycerides, and total cholesterol (hyperlipidemia) have a greater risk of coronary artery disease (168). Total cholesterol, LDL-C, APOB, LP(A), and the APOA1/APOB proportions are also excellent biomarkers for predicting CVDs in people [162].

**Low-density lipoprotein cholesterol**
A high plasma concentration of low-density lipoprotein cholesterol (LDLC) is a crucial risk factor for atherosclerotic cardiovascular disease (ACD). Furthermore, a rapid increase in LDLC plasma content suggests a significant risk of cardiovascular disease and necessitates faster therapeutic intervention [163]. Similarly, autosomal dominant hypercholesterolemia (ADH) is characterized by high LDL cholesterol, which causes early morbidity and death due to atherosclerotic cardiovascular disease (ASCVD). Similarly, familial combination hyperlipidemia (FCHL) is characterized by elevated total cholesterol, triglycerides, or LDL cholesterol and a significant risk of ASCVD [164]. LRPI (low-density lipoprotein receptor-related protein 1) is a large endocytic and signalling...
receptor mainly found in the liver, where it regulates blood coagulation factor VIII plasma levels by controlling its absorption and subsequent degradation. Similarly, tiny dense LDL cholesterol is a new risk factor for cardiovascular disease [165].

**Lipoprotein-associated phospholipase A2 (LP-PLA2)**

Lipoprotein-associated phospholipase A2 (LP-PLA2) is an enzyme that functions in blood vessel inflammation and is thought to contribute to atherosclerosis. This test determines how much LP-PLA2 is present in the blood. Recent research has shown that LP-PLA2 is a standalone risk factor for cardiovascular disease (CVD), including coronary heart disease (CHD) and ischemic stroke [166]. The sensitivity C-reactive protein (HS-CRP) test is linked to systemic inflammation, and higher levels are linked to an increased risk of cardiovascular disease. The LP-PLA2 test is linked to vascular inflammation and is considered to raise the risk of cardiac events, such as heart attack or stroke, at high levels. In persons with diabetes, a high level of LP-PLA2 is linked to vascular problems such as kidney damage [167]. Although it is a risk factor for heart disease, decreasing LP-PLA2 activity with medication is not advised for people with stable CHD [168].

**Oxylipin**

Oxylipins are bioactive lipid metabolites formed when polyunsaturated fatty acids are oxidized by the cyclooxygenase (COX), lipoxygenase, and cytochrome p450 pathways. They have a role in immunological, inflammatory, and vascular activities [169]. Abnormal oxylipin signaling has also been associated with CVD risk factors such as hypertension, hyperlipidemia, thrombosis, haemostasis, and diabetes. Oxylipins are a new age of risk indicators in numerous illnesses, including cardiovascular disease, and various oxylipins have a role in CVD development, albeit the mechanism is yet unknown [170].

**Pre-disease biological marker**

**Hypertension (HTN)**

Hypertension is a disease of the modern world. Although it seldom causes symptoms, it affects 16% to 37% of the world's population and is a significant risk factor for coronary artery disease, stroke, HF, and atrial fibrillation (AF) [171]. The available data support the claim that blood pressure (BP) monitoring is a substantial predictor of long-term risk and that it is better than clinic blood pressure measurement for this purpose. As a result, BP measurement combines higher precision with cheap cost and ease of application. According to American and European standards, all patients with known or suspected hypertension should have their BP checked and controlled at home [172, 173].

**Nucleic acid-derived biomarkers**

**MicroRNAs (miRNAs)**

MicroRNAs (miRNAs) are noncoding RNA molecules with a short length. They act via the seed region, a six- to an eight-nucleotide sequence that binds to messenger ribonucleic acid (mRNA) known as miRNA targets [174]. They primarily inhibit gene expression by downregulating translation at the post-expression stage, using two fundamental pathways: translational repression and mRNA degradation. The most reliable approach for quantitatively comparing miRNA expression levels is a real-time quantitative polymerase chain reaction, which has been the cornerstone of miRNA quantification. Lipid metabolism, glucose homeostasis, vascular integrity, and endothelial cell function are only a few pathways influenced by miRNA control [175, 176]. Earlier studies revealed that a miRNA panel's combined utility enhanced the predictive value of classic Framingham risk models, but no single miRNA imparted a clinically relevant reduction in acute MI risk [177].

**Genome-based biomarkers**

**Soluble ST2**

Over the last decade, more research has revealed that soluble ST2 is substantially more significant in people with heart failure and can aid with risk assessment for both acute and chronic heart failure. The US Food and Drug Administration recently approved a commercial-grade soluble ST2 assay (Presage, Critical Diagnostics, San Diego, CA) for use in chronic heart failure prognosis [49, 178, 179].

**Blood gene expression in CAD**

The Corus CAD (CardioDx, Palo Alto, CA) assay is now commercially available for this gene expression test. By standard protein biomarkers, the test is confined to patients with chest pain who do not have diabetes, chronic inflammatory illnesses, increased leukocyte levels, or acute coronary syndromes. The clinical efficacy of a transcriptome profile Corus CAD must be extensively validated against these current noninvasive standards and investigated in various groups [180, 181].

**DEFA1/DEFA3**

DEFA1/DEFA3 were the most strongly linked with CHD development among eight possible markers in a cross-sectional study of CHD prediction biomarkers in non-familial hyperlipidemia patients, and show promise for further application as inflammatory markers to
synergistically predict the risk of CHD development in Thai hyperlipidemia patients [182, 183].

Conclusions
Over the last decade, various efforts have been undertaken to discover meaningful biomarkers for cardiovascular disease risk management. The search for the most beneficial and ideal cardiovascular indicators will likely go on forever. Many ancient and innovative substances will be studied as single markers and in multi-marker techniques in the future years. We explored the notion that an ideal cardiovascular biomarker may simultaneously provide clinicians with a range of information concerning predictive, diagnostic, and prognostic implications, in addition to satisfying the conventional biomarker designation requirements. Based on the gathered data, a few circulating molecules seem to be of interest in this regard since they can provide all the clinical data described above. However, further research is needed before an effective platform for biomarker analysis that may replace conventional CVD diagnosis in clinical practice can be provided. Innovative targets are expected to be discovered due to the expansion of public biomarker databases, advancements in the sensitivity and selectivity of analytical techniques, and the development and routine use of innovative platforms with proven potential.

Acknowledgements
Authors would like to thank Osmania University and University of Hyderabad for providing the moral support for continuing our research.

Author contributions
ST and RP provided the concept and overlook the preparation of this manuscript; other authors include SSRN; HR and SC contribute equally to complete this gathering relative information, proof reading and finalizing for the submission of the article. All authors have read and approved the manuscript.

Funding
None of the funding are available to complete this article.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
None of human and animals are used to complete this article, and this study does not require any ethical statement to present.

Consent for publication
Not applicable.

Competing interests
None of the other authors has any conflicts of interest, financial or otherwise, to disclose.

Author details
1 Department of Biochemistry, Osmania University, Amberpet, Hyderabad, Telangana 500007, India. 2 Department of Plant Sciences, University of Hyderabad, Gopanpalle, Hyderabad, Telangana 500019, India. 3 Department of Genetics, Osmania University, Amberpet, Hyderabad, Telangana 500007, India.

References
1. Al-Mawali A (2015) Non-communicable diseases: shining a light on cardiovascular disease, Oman’s biggest killer. Oman Med J 30(4):227
2. Thomas H, Diamond J, Vecco A, Chaudhuri S, Shinnar E, Cromer S, Perel P, Mensah GA, Narula J, Johnson CO (2018) Global atlas of cardiovascular disease. Glob Heart 13:143–163
3. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A (2016) Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 4(13):256
4. van Kimmenade RR, Januzzi JL Jr (2012) Emerging biomarkers in heart failure. Clin Chem 58(1):127–138
5. Haidar A, Bengs S, Luu J, Osto E, Siller-Matula JM, Muka T, Gebhard C (2020) Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome. Eur Heart J 41(13):1328–1336
6. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379(22):2097–2107
7. AlGawwam G, Shalek ME (2021) Evaluation of glycogen phosphorylase BB (GPBB) level in serum as marker in diagnosis of acute ischemic stroke. Indian J Forensic Med Toxicol 15(3):1603–1608
8. El-Nagdy SA, Alfakhary V, Etewa R (2020) Role of glycogen phosphorylase in prediction of cardiotoxicity associated with acute carbon monoxide poisoning. Zagazig J Forensic Med 18(2):59–74
9. Migocka-Patrzalek M, Elias M (2021) Muscle glycogen phosphorylase and its functional partners in health and disease. Cells 10(4):883
10. Apple FS, Wu AH, Mair J, Ravkilde J, Pagani F, Christensen RH, Mockel M, Danne O (2005) Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chim Acta 351(5):810–824
11. Krause E-G, Rabitzsch G, Noll F, Mair J, Puschendorf B (1996) Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischemic injury and infarction. Mol Cell Biochem 160(1-2):289–295
12. Singh N, Rathore V, Mahat RK, Rastogi P (2018) Glycogen phosphorylase BB: a more sensitive and specific marker than other cardiac markers for early diagnosis of acute myocardial infarction. Indian J Clin Biochem 33(3):356–360
13. Newgard CB, Hwang PK, Fletterick RJ (1989) The family of glycogen phosphorylases: structure and function. Crit Rev Biochem Mol Biol 24(1):69–99
14. Park K-Y, Ay I, Avery R, Caceres JA, Siket MS, Pontes-Neto OM, Zheng H, Rost NS, Furie KL, Sorensen AG (2018) New biomarker for acute ischemic stroke: plasma glycogen phosphorylase isozyme BB. J Neurol Neurosurg Psychiatry 89(4):404–409
15. Peetz D, Post F, Schinzl H, Schweigert R, Schollmayer C, Steinbach K, Dati F, Noll F, Lackner KJ (2005) Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med (CCLM) 43(12):1351–1358
16. Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, Krause E-G, Dienstl F, Puschendorf B (1995) Immunoenzymometric assay of human glycogen phosphorylase isozyme BB in diagnosis of ischemic myocardial injury. Clin Chem 41(7):966–978
17. Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, Krause E-G, Dienstl F, Puschendorf B (1993) Isoenzyme BB of glycogen phosphorylase BB in acute myocardial infarction. Lancet 341(8851):1032–1033
18. Wild PS, Schnabel RB, Lubos E, Zeller T, Sinning CR, Keller T, Tzikas S, Lackner KJ, Peetz D, Rupprecht HJ (2012) Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the Atheo Gene Study. Clin Chem 58(12):226–236
19. Parsanathan R, Jain SK (2020) Novel invasive and noninvasive cardiac-specific biomarkers in obesity and cardiovascular diseases. Metab Syndr Relat Disord 18(1):10–30
20. Dolci A, Pantechnini M (2006) The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. Clin Chim Acta 369(2):179–187
21. Ladenson JH (2007) A personal history of markers of myocyte injury [myocardial infarction]. Clin Chim Acta 381(1):3–8

Received: 19 April 2022   Accepted: 10 October 2022
Published online: 20 October 2022
23. Lee N, Barthel SR, Schatton T (2014) Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest 94(1):13–30
24. Series CC, Challenge E, Mind OM, Doodle C (1979) Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 59(3):607–609
25. Yamaguchi S, Abe M, Arakaki T, Arasaki O, Shimabukuro M (2020) Prognostic value of lactate dehydrogenase for mid-term mortality in acute decompensated heart failure: a comparison to established biomarkers and brain natriuretic peptide. Heart Lung Circ 29(9):1318–1327
26. Aly M, Naylor M, Salama A, Ghazy E, Elshahawy I (2020) Cardiac troponin I as a cardiac biomarker has prognostic and predictive value for poor survival in Egyptian buffalo calves with foot-and-mouth disease. Vet World 13(5):890
27. Schmiechen NJ, Han C, Milzman DP (1997) ED use of rapid lactate to evaluate patients with acute chest pain. Ann Emerg Med 30(5):571–577
28. Yun DD, Alpert JS (1997) Acute coronary syndromes. Cardiology 88(3):223–237
29. Silagi ES, Batista P, Shapiro IM, Risbud MV (2018) Expression of carbonic anhydrase III, a nucleus pulposus phenotypic marker, is hypertrophy responsive and confers protection from oxidative stress-induced cell death. Sci Rep 8(1):1–13
30. Dowling P, Gargan S, Zweyer M, Sabir H, Swandulla D, Ohlendieck K (2021) Proteomic profiling of cardiac anhydrase CA3 in skeletal muscle. Expert Rev Proteomics 18:1–14
31. Zamanova S, Shabana AM, Mondal UK, Doodle C (1979) Carbonic anhydrase as disease markers. Expert Opin Ther Pat 29(7):509–533
32. Feng H-Z, Jin J-P (2019) Transgenic expression of carbonic anhydrase III in cardiac muscle demonstrates a mechanism to tolerate acidosis. Am J Physiol Cell Physiol 317(5):C922–C931
33. Zhang X-M, Tao Y-H, Zhou X-L, Shang X-L, Gong X-B, Liu Y-C, Huang Y-Y, Chen G, Yu Z-Y, Wang J-T (2021) The role of carbonic anhydrase III and autophagy in type 2 diabetes with cardio-cerebrovascular disease. Metab Brain Dis 36(2):2329–2341
34. Kim YS, Karisa N, Jeon WY, Lee H, Kim Y-C, Ahn J (2019) High-level production of N-terminal pro-brain natriuretic peptide, as a calibrator of heart failure diagnosis, Ershischeria coli. Appl Microbiol Biotechnol 103(12):4779–4788
35. York MK, Gupta DK, Reynolds CF, Farber-Eger E, Wells QS, Bachmann KN, Xu M, Hanrell FE, Wang Tj (2018) B-type natriuretic peptide levels and mortality in patients with and without heart failure. J Am Coll Cardiol 71(19):2079–2088
36. Almeida Junior GLGd, Braga F, Jorge JK, Nobre GF, Kalichsztein M, Faria RdsMPd, Bussade B, Penna GL, Alves VO, Pereira MA (2020) Prognostic value of troponin-T and B-type natriuretic peptide in patients hospitalised for COVID-19. Arq Bras Cardiol 115:660–666
37. Ghomian N, Vakilian F, Shahri B, Rostaminejad V, Khadem-Rezaiyan M (2019) Can brain natriuretic peptide predict cardiovascular complications in severe preeclampsia? A case-control study. Int J Reprod BioMed 17(4):271
38. Wong Y-K, Cheung CY, Tang CS, Hai Y, Lee C-H, Yee P, Cheung BM, Sham P-C, Xu A (2019) High-sensitivity Troponin I and B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction. Medicine 97(38):e12277
39. Li X, Liu C, Mao Z, Qi S, Song R, Zhou F (2020) Brain natriuretic peptide for predicting contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography: a systematic review and meta-analysis. Int J Cardiol 2020:1035089
40. Cui K, Huang W, Fan J, Lei H (2018) Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction. Medicine 97(36):e12277
41. Perez MO, Winther JA, Brynildsen J, Strand H, Christensen G, Häseth AD, Myhrre P, Raynolds RR, Lyngbakken MH, Omland T (2018) Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study. Biomarkers 23(7):654–663
42. Gauthin E, Chisalita SI, Engvall J, Nyström FH, Östgren CJ (2021) Plasma mid-regional pro-atrial natriuretic peptide predicts cardiovascular events in patients with type 2 diabetes independently of subclinical organ damage. Diabetes Res Clin Pract 182:109095
43. Francis GS, Felker GM, Tang WW (2016) A test in context: critical evaluation of natriuretic peptide testing in heart failure. J Am Coll Cardiol 67(3):330–337
44. Koyama T, Kuriyama N, Suzuki Y, Saito S, Tanaka R, Iwao M, Tanaka M, Maki T, Itoh H, Isara M (2021) Mid-regional pro-adrenomedullin is a novel biomarker for arterial stiffness as the criterion for vascular failure in a cross-sectional study. Sci Rep 11(1):1–7
45. Czajkowska K, Zbroch E, Bielach-Bazyluk A, Mitrosz K, Bujna E, Kakareko K, Rydzewska-Rosolowska A, Hryszyko T (2021) Mid-regional proadrenomedullin as a new biomarker of kidney and cardiovascular diseases—is it the future? J Clin Med 10(5):524
46. van Oers JA, Kluiters B, Jonk J, Mokkelsma S, Ramnarain D, de Lange DW, de Grooth H-J, Girbes AR (2021) Endothelin-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: a prospective cohort study. J Crit Care 66:173–180
47. Bustamante A, García-Berrocoso T, Penalba A, Giralt D, Simats A, Mucheda M, Zapata E, Rubiera M, Montaner J (2017) Sepsis biomarkers reprofilling to predict stroke-associated infections. J Neuroimmunol 312:19–23
48. Dres M, Hauspater P, Feissac F, Bernard M, Joly L-M, Sebbane M, Philippon A-L, Gil-Jardínez C, Schmidt J, Maigman M (2017) Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. Int J Chron Obstr Pulm Dis 12:1047
49. Lopes D, Falcao LM (2017) Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis. Rev Port Cardiol (English Edition) 36(6):465–472
50. Hultmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T, Berger R, Woloszczuk W, Maurer G, Pachler R (1998) Value of cardipulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 32(6):1695–1700
51. Kempt T, Wollert KC (2009) Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz 34(8):594–599
52. Jankovich M, Choudhary G (2020) Endothelin-1 levels and cardiovascular events. Trends Cardiovasc Med 30(1):1–8
53. Obokata M, Kane GC, Reddy YN, Melinovsky V, Olsson TP, Jarolim P, Borlaug BA (2019) The neurohumoral basis of pulmonary hypertension in heart failure with preserved ejection fraction. Eur Heart J 40(45):3707–3717
54. Then C, Thorand B, Then H, Meisinger C, Heier M, Peters A, Koenig W, Rathmann W, Billigmeier M, Lechner A (2020) Serum uromodulin is inversely associated with arterial hypertension and the vasocostrictive prohormone CT-proET-1 in the population-based KORA F4 study. PLoS ONE 15(8):e0237364
55. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, Braunwald E (2012) Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 125(2):233–240
56. Al-Hadi HA, Fox KA (2009) Cardiac markers in the early diagnosis and management of patients with acute coronary syndrome. Sultan Qaboos Univ Med J 9(3):231
57. Guzy PM (1977) Creatine phosphokinase-MB (CPK-MB) and the diagnosis of myocardial infarction. Br Heart J 25(6):795
58. Elliott B, Jepson E, Wilkinson J (1962) Serum alpha-hydroxybutyrate dehydrogenase-a new test with improved specificity for myocardial infarction. Clin Sci 23(2):305
59. Rosalki S (1963) Serum alpha-hydroxybutyrate dehydrogenase: a new test for myocardial infarction. Br Heart J 25(6):795
60. Elliott B, Wilkinson J (1963) Serum alpha-hydroxybutyrate dehydrogenase in diseases other than myocardial infarction. Clin Sci 24(3):343–350
61. Chan D, Ng LL (2010) Biomarkers in acute myocardial infarction. BMC Med 8(1):1–11

62. Haltern G, Peiniger S, Bule A, Reiss G, Gucker H, Scheffold T (2010) Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardio 105(1–11)

63. Mad P, Domanovits H, Fazelnia C, Stiassny K, Russmüller G, Cseh A, Sodeck G, Binder T, Christ G, Szereres T (2007) Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction. J Assoc Physicians 100(4):203–210

64. Ruzzo R, Bilge AK, Bugra Z, Ummann S, Yilmaz E, Ozben B, Ummann B, Meric M (2006) The use of human heart-type fatty acid-binding protein as an early diagnostic biochemical marker of myocardial necrosis in patients with acute coronary syndrome, and its comparison with troponin-T and creatinine kinase–myocardial band. Heart Vessels 21(5):309–314

65. Brown CS, Bentolet BD (1997) Cardiac troponin: see ya later, CK! Chest 111(1–2)

66. Du Clos TW (2000) Function of C-reactive protein. Ann Med 32(4):274–278

67. Clearfield MB (2005) C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 105(9):409–416

68. Chandra P, Suman P, Airon H, Mukherjee M, Kumar P (2014) Prospects and advancements in C-reactive protein detection. World J Methodol 4(1):1

69. Chrysohoou C, Pitsavos C, Barbetseas J, Kotroyiannis I, Brili S, Vasiliadou K, Papadimitriou L, Stefanadis C (2009) Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). Heart Vessels 24(1):22–26

70. Rivera M, Taléns-Visconti R, Sirera R, Bertomeu V, Salvador A, Cortés R, de Burgos FG, Climent V, Payá R, Martinez-Dolz L (2004) Soluble TNF-α and interleukin-6 receptors in the urine of heart failure patients. Their clinical value and relationship with plasma levels. Eur J Heart Fail 6(7):877–882

71. Wollert KC, Drexler H (2001) The role of interleukin-6 in the failing heart. Heart Fail Rev 6(2):95–103

72. Gabriele R, Zhi Fang S, Tonny DTT, Carsten K, Hideo AB, Michael E, Markus F, Thomas W, Hans HS, Mario CD (2001) Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail 3(4):415–421

73. Raymond RJ, Dehmer GJ, Theoharides TC, Delargyris EN (2001) Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am J Heart Fail 14(1):435–438

74. Pudli R, Tichy M, Andrýs C, Reháček V, Bláha V, Vojáček J, Palicka V (2010) Plasma interleukin-6 level is associated with NT-proBNP level and predicts short-and-long-term mortality in patients with acute heart failure. Acta Medica (Hradec Kralove) 53(4):225–228

75. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmer R, van den Brand MJ, Boersma E, van den Brand MJ, Boersma E, Zehier AM, Simoons ML (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348(12):1104–1111

76. Neuhold S, Hueltsmann M, Strunk G, Stoiener B, Struck J, Morgensthe NG, Bergmann A, Moert J, Berger R, Pacher R (2008) Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 52(4):266–272

77. Morgensthe NG, Struck J, Alonso C, Bergmann A, Squire I, Van Veldhuisen DJ, Dickstein K (2009) C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAAL study. Eur Heart J 30(10):1187–1194

78. Rechlin T, Hochholzer W, Stegb C, Laule K, Freidhank H, Morgensthe NG, Bergmann A, Potocki M, Novea M, Breidthardt T (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54(1):60–68

79. Wollert KC, Kempf T (2012) Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 9(4):337–345

80. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Mokk信t JD (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98(3):342–350

81. Kempf T, Bjorklund E, Oldfors S, Lindahl B, Alhoff F, Peter T, Tonders J, Wollert KC, Wallentin L (2007) Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 28(23):2885–2895

82. Kempf T, von Haehling S, Peter T, Alhoff F, Ticoa M, Doehner W, Ponikowski P, Filipatos GS, Zoventz P, Drexler H (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50(11):1054–1060

83. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117(6):1538–1549

84. Weinberg EO, Shipp M, Hurwitz S, Tomlinson J, Roulue J-L, Lee RT (2003) Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107(5):721–726

85. Rehman SU, Mueller T, Januzzi JL (2008) Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52(18):1458–1465

86. Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Lee RT (2007) Measurement of the interleukin family member ST2 in patients with chronic heart failure predicts outcome in patients with congestive heart failure. Circulation 116(15):e31479–e31480

87. Rehman SU, Mueller T, Januzzi JL (2008) Prognostic utility of pro-brain natriuretic peptide in acute coronary syndromes: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 51(7):607–613

88. López B, Ravassa S, González A, Zubillaga E, Bonavía C, Bergós M, Echegaray K, Beaumont J, Moreno MU, San José G (2016) Myocardial collagen crosslinking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 67(3):251–260

89. George J, Patal A, Wexler D, Roth A, Sheds D, Keren G (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150:484–487

90. Burali S, Dini FL, Ballo P, Conti U, Fontanive P, Duranti E, Metelli MR, Marzilli M, Taddei S (2010) Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction in patients with heart failure: an independent predictor of mortality. Eur J Heart Fail 12(10):388–395
myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 30(10):1229–1236
140. Damman K, Masson S, Hillege HL, Magniioni AP, Voon AA, Opasich C, Van Weldenhoef DJ, Montagna L, Cosmi F, Tognoni G (2011) Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 32(21):2705–2712
141. Fabbriini E, Serafini M, Baric IC, Hazen SL, Klein S (2014) Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes 63(3):976–981
142. Jin YL, Zhu T, Xu L, Zhang WS, Liu B, Jiang CQ, Yu H, Huang LM, Cheng KK, Thomas GN (2013) Uric acid levels, even in the normal range, are associated with increased cardiovascular risk. The Guangzhou Biobank Cohort Study. Int J Cardiol 168(3):2238–2241
143. Dutta A, Henley W, Pilling LC, Wallace RB, Melzer D (2013) Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am GenIntern Sci 61(3):319–326
144. Zhao G, Huang L, Song M, Song Y (2013) Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 231(1):61–68
145. Fenech G, Razbaun G, Maziighi M, Blacher J (2014) Serum uric acid and cardiovascular risk: state of the art and perspectives. Joint Bone Spine 81(3):392–397
146. Jin Y, Lee SY, Kim MT (2004) Serum uric acid and risk of death from cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil 11(3):185–191
147. Lee K-F, Simon H, Chen H, Bates B, Hung M-C, Hauser C (1995) Requirement for neutrophil elastase-receptor in neu- ronal and cardiac development. Nature 376(6555):394–398
148. Kuramochi Y, Cote GM, Guo X, Lebrasseur NK, Cui L, Liao R, Sawyer DB (2004) Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neutrophil-1/erbB4 signaling. J Biol Chem 279(49):51411–51417
149. Lemmens K, Doggen K, De Keulenaer GW (2007) Role of uric acid as a risk factor for cardiovascular disease and glucose intolerance in women. Atherosclerosis 193(2):446–451
150. Arques S (2018) Human serum albumin in cardiovascular diseases. Eur J Intern Med 52:8–12
151. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB, Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Topbas C, Swick A, Razavi M, Anderson NL, Pearson TW, Bystrom C (2018) Measurement of lipoprotein-associated phospholipase A2 by use of three different methods: exploration of discordance between ELISA and activity assays. Clin Chim Acta 479:69–704
152. Investigators S (2014) Dapagliflozin for preventing ischemic events in stable coronary heart disease. N Engl J Med 370(18):1702–1711
153. Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Haggstrom E, Harrington RA, Hochman JS, Koenig W (2016) Cardiovascular disease, interleukin-6, and risk of mortality as a predictor of cardiovascular disease related mortality: results from the large AtheroGene study. Eur Heart J 38(7):516–523
154. Nayeem MA (2018) Role of oxylipins in thrombosis and diabetes. Front Pharmacol 4:176
155. Pickering TG, Miller NH, Ogedegbe G, Kackoff LR, Arterian NT, Goff D (2008) Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 52(1):10–29
156. Parati G, Stengou GS, Asmar R, Bilo G, De Leeuw P, Imai Y, Kario K, Lurbie E, Manolis A, Mengden T (2008) European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 26(8):1505–1526
157. Barswari T, Joshi A, Maye M (2016) MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 68(23):2577–2584
158. Dimmeler S, Zeiher AM (2010) Circulating microRNAs: novel biomarkers for cardiovascular diseases? Journal 31:2705–2707
159. Karakas M, Schulte C, Appelbaum S, Ojeda F, Lackner KJ, Münzel T, Schnabel RB, Blankenberg S, Zeller T (2017) Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study. Eur Heart J 38(7):516–523
160. Zampetaki A, Willett P, Tilling L, Drozdov I, Prokopi M, Renard J-M, Maye M, Ager W, Schett G, Shah A (2012) Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 60(4):390–399
161. Kim AJ, Ro H, Kim H, Chang JH, Lee HH, Chung W, Jung JY (2021) Stable SOL and galectin-3 as predictors of chronic kidney disease progression and outcomes. Am J Nephrol 52(2):119–130
162. Li C, Zhao M, Zhao M, Chen N, Guo Y, Du Y, Zhang Y, Cao B, Zhan B, Guo C (2022) IL-37 isofroms D acts as an inhibitor of soluble ST2 to boost type 2 immune homeostasis in white adipose tissue. Cell Death Discov 8(1):1–12
163. Parikh A, Lockwood S, White A, Yang J, Young MI (2022) Mineralocorticoid receptor antagonists, heart failure and predictive biomarkers. J Endocrinol 253(3):R65–R70
181. Mincarone P, Bodini A, Tumolo MR, Vozzi F, Rocchiccioli S, Pelosi G, Caselli C, Sabina S, Leo CG (2021) Discrimination capability of pretest probability of stable coronary artery disease: a systematic review and meta-analysis suggesting how to improve validation procedures. BMJ Open 11(7):e047677

182. Kanmura S, Morinaga Y, Tanaka A, Komaki Y, Iwaya H, Kumagai K, Mawatari S, Sasaki F, Tanoue S, Hashimoto S (2021) Increased gene copy number of DEFA1A3 is associated with the severity of ulcerative colitis. Clin Transl Gastroenterol 12(4):e00331

183. Deng H, Li J, Shah AA, Lin G, Chen H, Ouyang W (2022) Commonly expressed key transcriptomic profiles of sepsis in the human circulation and brain via integrated analysis. Int Immunopharmacol 104:108518

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.